These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29365407)

  • 1. [Efficacy and safety of recombinant human thrombopoietin combined with hormonal and cyclosporine in 20 patients with newly diagnosed immune-related pancytopenia].
    Qian J; Lu W; Yang L; Zhang YP; Yang X; Lin ZH; Liu H
    Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1078-1081. PubMed ID: 29365407
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia.
    Wang X; Bi H; Liu L; Liu Y; Yin L; Yao J; Yu J; Tao W; Wei Y; Li Y; Yin L; Mu H; Du Y; Zhou Z
    Platelets; 2023 Dec; 34(1):2271568. PubMed ID: 37941414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical Analysis of Recombinant Human Thrombopoietin for Treatment of 46 Adult Patients with Newly Diagnosed Primary Immune Thrombocytopenia].
    Wang M; Liu YF; Sun H; Xie XS; Ma J; Gan SL; Dong YJ; Ren HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):531-5. PubMed ID: 27151024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The Treatment of Newly Diagnosed Primary Immune Thrombocytopenia by Recombinant Human Thrombopoietin Combined with Glucocorticoid].
    Yuan J; Li LY; Wang ZZ; Liu XJ; Yang L; Luo JM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):832-835. PubMed ID: 35680813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A clinical comparative study on treatment of severe newly diagnosed immune thrombocytopenia by recombinant human thrombopoietin combined with glucocorticoid].
    Gu SY; Zhuang JL; Zou SH; Li F; Wang ZM; Cheng YF; Wang WG; Cheng ZX; Yuan L; Cheng LY; Wei Z
    Zhonghua Xue Ye Xue Za Zhi; 2013 Oct; 34(10):883-6. PubMed ID: 24171964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice.
    Iino M; Sakamoto Y; Sato T
    Int J Hematol; 2020 Aug; 112(2):159-168. PubMed ID: 32476083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor.
    Basser RL; O'Flaherty E; Green M; Edmonds M; Nichol J; Menchaca DM; Cohen B; Begley CG
    Blood; 2002 Apr; 99(7):2599-602. PubMed ID: 11895799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the safety and efficacy of recombinant human thrombopoietin among severe sepsis patients with thrombocytopenia: study protocol for a randomized controlled trial.
    Wu Q; Ren J; Wang G; Gu G; Hu D; Liu S; Li G; Chen J; Li R; Hong Z; Ren H; Wu X; Li Y; Yao M; Zhao Y; Li J
    Trials; 2015 May; 16():220. PubMed ID: 25986785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment characteristics, efficacy and safety of thrombopoietin analogues in routine management of primary immune thrombocytopenia.
    Mingot-Castellano ME; Caparrós IS; Fernández F; Perera-Alvarez MDM; Jimenez-Bárcenas R; Casaus García A; González-Silva M; Yera-Cobo M; Nieto-Hernandez MM; Rodríguez-Fernandez MJ; Díaz-Canales D
    Blood Coagul Fibrinolysis; 2018 Jun; 29(4):374-380. PubMed ID: 29738335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of up-front treatments for newly diagnosed immune thrombocytopenia -a systematic review and network meta-analysis.
    Arai Y; Jo T; Matsui H; Kondo T; Takaori-Kondo A
    Haematologica; 2018 Jan; 103(1):163-171. PubMed ID: 28971908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial.
    Yu Y; Wang M; Hou Y; Qin P; Zeng Q; Yu W; Guo X; Wang J; Wang X; Liu G; Chu X; Yang L; Feng Y; Zhou F; Sun Z; Zhang M; Wang X; Wang Z; Ran X; Zhao H; Wang L; Zhang H; Bi K; Li D; Yuan C; Xu R; Wang Y; Zhou Y; Peng J; Liu XG; Hou M
    Am J Hematol; 2020 Dec; 95(12):1542-1552. PubMed ID: 32871029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune pancytopenia following chronic immune thrombocytopenia: Case report and literature review.
    Gardellini A; Guidotti F; Zancanella M; Saccà V; Feltri M; Ambrosiani L; Turrini M
    Blood Cells Mol Dis; 2020 Sep; 84():102455. PubMed ID: 32502698
    [No Abstract]   [Full Text] [Related]  

  • 13. A single dose of thrombopoietin shortly after myelosuppressive total body irradiation prevents pancytopenia in mice by promoting short-term multilineage spleen-repopulating cells at the transient expense of bone marrow-repopulating cells.
    Neelis KJ; Visser TP; Dimjati W; Thomas GR; Fielder PJ; Bloedow D; Eaton DL; Wagemaker G
    Blood; 1998 Sep; 92(5):1586-97. PubMed ID: 9716586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo biological effects of various forms of thrombopoietin in a murine model of transient pancytopenia.
    Thomas GR; Thibodeaux H; Errett CJ; Mathias J; Marian M; Meng G; Vandlen RL; Eaton DL
    Stem Cells; 1996; 14 Suppl 1():246-55. PubMed ID: 11012228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of romiplostim among patients with newly diagnosed, persistent and chronic ITP in routine clinical practice in central and Eastern Europe: an analysis of the PLATON study.
    Skopec B; Sninska Z; Tzvetkov N; Ivanushkin V; Björklöf K; Hippenmeyer J; Mihaylov G
    Hematology; 2021 Dec; 26(1):497-502. PubMed ID: 34238136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of treatments in newly diagnosed adult primary immune thrombocytopenia: A systematic review and network meta-analysis.
    Wang Y; Sheng L; Han F; Guo Q; Zhang Z; Hou Y; Feng Q; Zhou H; Ji X; Peng J; Hou M; Xu M
    EClinicalMedicine; 2023 Feb; 56():101777. PubMed ID: 36578882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eltrombopag treatment of a dog with idiopathic aplastic pancytopenia.
    Kelly D; Lamb V; Juvet F
    J Vet Intern Med; 2020 Mar; 34(2):890-892. PubMed ID: 32096575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of the efficacy of cyclosporin A combined with recombined human thrombopoietin for treating patients with non-severe aplastic anemia].
    Zhang ML; Chen WS; Han B
    Zhonghua Xue Ye Xue Za Zhi; 2020 Aug; 41(8):637-642. PubMed ID: 32942816
    [No Abstract]   [Full Text] [Related]  

  • 19. Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia.
    Lozano ML; Godeau B; Grainger J; Matzdorff A; Rodeghiero F; Hippenmeyer J; Kuter DJ
    Expert Rev Hematol; 2020 Dec; 13(12):1319-1332. PubMed ID: 33249935
    [No Abstract]   [Full Text] [Related]  

  • 20. Recombinant human thrombopoietin in combination with cyclosporin A as a novel therapy in corticosteroid-resistant primary immune thrombocytopenia.
    Cui ZG; Liu XG; Qin P; Hou M; Wu SL; Peng J; Zhao HG; Wang HY; Zhao CT
    Chin Med J (Engl); 2013 Nov; 126(21):4145-8. PubMed ID: 24229688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.